Heikki Matti Kalervo Hautsalo

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.

Aura Capital Oy (Aura Capital) is a private equity/venture capital subsidiary of Auratum Oy founded in 1997. The firm is headquartered in Turku, Finland.

IP Finland Oy provides research and development services. It specializes in the commercialization of research-based intellectual property. The company is headquartered in Helsinki, Finland.

AdaptaMat Oy engages in the manufacture of NiMnGa-based Magnetic Shape Memory (MSM) alloys. MSM is also referred to as Ferromagnetic Shape Memory alloy. It offers MSM single-crystals and has demonstrated several MSM-based devices such as vibration energy harvesting, displacement sensors and actuators with self-sensing capability for positioning and proportional control. The company was founded in 1996 and is headquartered in Helsinki, Finland.

Optomed Software Oy develops and sells proprietary software solutions for healthcare organizations. It offers products for workflow, resource and quality management within radiological or surgical departments or any screening or follow-up program. The company was founded in 1989 and is headquartered in Espoo, Finland.